Advertisement

Drugs & Aging

, Volume 16, Issue 6, pp 397–407 | Cite as

Onychomycosis in the Elderly

Disease Management

Abstract

Onychomycosis is found more frequently in the elderly, and in more males than females. Onychomycosis of the toes is usually caused by dermatophytes, most commonly Trichophyton rubrum and T. mentagrophytes. The most common clinical presentations are distal and lateral subungual onychomycosis (which usually affects the great/first toe) and white superficial onychomycosis (which generally involves the third/fourth toes). Only about 50% of all abnormal-appearing nails are due to onychomycosis. In the remainder, trauma to the nail, psoriasis and conditions such as lichen planus should be considered in the differential diagnosis. Therefore, the clinical impression of onychomycosis should be confirmed by mycological examination, whenever possible.

The management of onychomycosis may include no therapy, palliative treatment with mechanical or chemical debridement, topical antifungal therapy, oral antifungal agents or a combination of treatment modalities. In the US, the only new oral agents approved for treatment of onychomycosis are terbinafine and itraconazole. Fluconazole is approved for onychomycosis in some other countries. Ciclopirox nail lacquer has recently been approved in the US for the treatment of onychomycosis. In some other countries topical agents such as amorolfine are also used. Griseofulvin and ketoconazole are no longer preferred for the treatment of onychomycosis.

The new oral antifungal agents are effective and well tolerated in the elderly. Patient selection should be based on the history (including systems review and medication record), examination and baseline monitoring, if indicated. Laboratory monitoring during therapy for onychomycosis varies among physicians. A combination of removal of the diseased nail plate or local measures and oral antifungal therapy may be optimal in certain instances, e.g. when lateral onychomycosis or dermatophytoma are present. For dermatophyte toe onychomycosis the recommended duration of therapy with terbinafine is 250 mg/day for 12 weeks. For itraconazole (pulse) the regimen is 200mg twice daily for 1 week on, 3 weeks off, repeated for 3 consecutive pulses and with fluconazole the regimen is 150 to 300mg once weekly given for a usual range of 6 to 12 months or until the nail plate has grown out. In some instances, if extra therapy is required, one suggestion is that 4 weeks of terbinafine or an extra pulse of itraconazole are given between months 6 and 9 from the start of therapy. Once cure has been achieved, it is important to counsel patients on the strategies of reducing recurrence of disease.

Keywords

Fluconazole Itraconazole Terbinafine Nail Plate Tinea Pedis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada: a multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783–7PubMedCrossRefGoogle Scholar
  2. 2.
    Zaias N. Onychomycosis. Dermatol Clin 1985; 3: 445–60PubMedGoogle Scholar
  3. 3.
    Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126Suppl. 39: 23–7PubMedCrossRefGoogle Scholar
  4. 4.
    Sais G, Juggla A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758–61PubMedCrossRefGoogle Scholar
  5. 5.
    Heikkila H, Stuff S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699–703PubMedCrossRefGoogle Scholar
  6. 6.
    Rigopoulos D. Epidemiology of onychomycosis in southern Greece. Int J Dermatol 1998; 37: 925–8PubMedCrossRefGoogle Scholar
  7. 7.
    Elewski B, Charif M. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions [letter]. Arch Dermatol 1997; 133: 1172–3PubMedCrossRefGoogle Scholar
  8. 8.
    Gupta AK, Sibbald G, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997; 36: 395–402PubMedCrossRefGoogle Scholar
  9. 9.
    Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997; 87: 546–50PubMedGoogle Scholar
  10. 10.
    Albright JW, Albright JF. Ageing alters the competence of the immune system to control parasitic infection. Immunol Lett 1994; 40: 279–85PubMedCrossRefGoogle Scholar
  11. 11.
    Hamilton JB, Terada H, Mestler GE. Studies of growth throughout the life span in Japanese: growth and size of nails and their relationship to age, sex heredity and other factors. J Gerontol 1955; 10: 401–15PubMedCrossRefGoogle Scholar
  12. 12.
    Helfand AE. Podiatry in a total geriatric health program: common foot problems of the aged. J Am Geriatr Soc 1967; 15: 593–9PubMedGoogle Scholar
  13. 13.
    Helfand AE. Nail and hyperkeratotic problems in the elderly foot. Am Fam Phys 1989; 39: 101–10Google Scholar
  14. 14.
    Baran R, Dawber RPR. The nail in dermatological diseases. In: Baran R, Dawber RPR, editors. Diseases of the nails and their management. 2nd ed. Oxford: Blackwell Scientific Publications, 1994: 135–73Google Scholar
  15. 15.
    Tosti A, Baran R, Dawber RPR. The nail in systemic diseases and drug-induced changes. In: Baran R, Dawber RPR, editors. Diseases of the nails and their management. 2nd ed. Oxford: Blackwell Scientific Publications, 1994: 175–262Google Scholar
  16. 16.
    Del Rosso JQ, Basuk PJ, Scher RK, et al. Dermatologic diseases of the nail unit. In: Scher RK, Daniel III CR, editors. Nails: therapy, diagnosis, surgery. 2nd ed. Philadelphia: W.B. Saunders Company 1997: 172–200Google Scholar
  17. 17.
    Daniel III CR, Sams Jr WM, Scher RK. Nails in systemic disease. In: Scher RK, Daniel III CR, editors. Nails: therapy, diagnosis, surgery. 2nd ed. Philadelphia: W. B. Saunders Company, 1997: 219–50Google Scholar
  18. 18.
    Daniel III CR, Scher RK. Nail changes secondary to systemic drugs and ingestants. In: Scher RK, Daniel III CR, editors. Nails: therapy, diagnosis, surgery. 2nd ed. Philadelphia: W. B. Saunders Company, 1997: 251–61Google Scholar
  19. 19.
    Daniel III CR. Pigmentation abnormalities. In: Scher RK, Daniel III CR, editors. Nails: therapy, diagnosis, surgery. 2nd ed. Philadelphia: W. B. Saunders Company, 1997: 201–18Google Scholar
  20. 20.
    Perrin C, Baran R. Longitudinal melanonychia caused by Trichophyton rubrum.. J Am Acad Dermatol 1994; 31: 311–6PubMedCrossRefGoogle Scholar
  21. 21.
    Baran R, Kechijian P. Longitudinal melanonychia (melanonychia striata): diagnosis and management. J Am Acad Dermatol 1989; 21: 1165–75PubMedCrossRefGoogle Scholar
  22. 22.
    Norton LA. Tumors. In: Scher RK, Daniel HI CR, editors. Nails: therapy, diagnosis, surgery. 2nd ed. Philadelphia: W. B. Saunders Company, 1997: 262–75Google Scholar
  23. 23.
    Zaias N. Onychomycosis. Arch Dermatol 1972; 105: 263–74PubMedCrossRefGoogle Scholar
  24. 24.
    Baran R, Hay RJ, Tosti A, et al. A new classification of onychomycosis. Br J Dermatol 1998; 139: 567–71PubMedCrossRefGoogle Scholar
  25. 25.
    Tosti A, Baran R, Piraccini BM, et al. ‘Endonyx’ onychomycosis: a new modality of nail invasion by dermatophytes. Acta Derm Venereol 1999; 79: 52–3PubMedCrossRefGoogle Scholar
  26. 26.
    Baran R. Proximal subungual Cundida onychomycosis: an unusual manifestation of chronic mucocutaneous candidosis. Br J Dermatol 1997; 137: 286–8PubMedCrossRefGoogle Scholar
  27. 27.
    Piraccini BM, Morelli R, Stinchi C, et al. Proximal subungual onychomycosis due to Micmsporum canis. Br J Dermatol 1996; 134: 175–7PubMedCrossRefGoogle Scholar
  28. 28.
    Silva-Lizama E, Logemann H. Proximal white subungual onychomycosis in AIDS. Int J Dermatol 1996; 35: 290–1PubMedCrossRefGoogle Scholar
  29. 29.
    Noppakun N, Head ES. Proximal white subungual onychomycosis in a patient with acquired immune deficiency syndrome. Int J Dermatol 1986; 25: 586–7PubMedCrossRefGoogle Scholar
  30. 30.
    Elewski BE. Clinical pearl: proximal white subungual onychomycosis in AIDS. J Am Acad Dermatol 1993; 29: 631–2PubMedCrossRefGoogle Scholar
  31. 31.
    Rongioletti F, Persi A, Tripodi S, et al. Proximal white subungual onychomycosis: a sign of immunodeficiency. J Am Acad Dermatol 1994; 30: 129–30PubMedCrossRefGoogle Scholar
  32. 32.
    Dompmartin D, Dompmartin A, Deluol AM, et al. Onychomycosis and AIDS: clinical and laboratory findings in 62 patients. Int J Dermatol 1990; 29: 337–9PubMedCrossRefGoogle Scholar
  33. 33.
    Weismann K, Knudsen EA, Pedersen C. White nails in AIDS/ARC due to Trichophyton rubrum. infection. Clin Exp Dermatol 1988; 13: 24–5PubMedCrossRefGoogle Scholar
  34. 34.
    Weinberg JM, Koestenblatt EK, Don PC, et al. Proximal white subungual onychomycosis in the immunocompetent patient: report of two cases and review of the literature. Acta Dermatol Venereol 1999; 9: 81–2CrossRefGoogle Scholar
  35. 35.
    Chang P, Arenas R. Proximal white subungual onychomycosis in a kidney transplant patient [letter]. Int J Dermatol 1995; 34: 591PubMedCrossRefGoogle Scholar
  36. 36.
    Gupta AK, Jain H, Lynde CW, et al. Prevalence of onychomycosis in 15 000 patients visiting dermatologists’ offices in London, Ontario, Canada [abstract]. J Eur Acad Dermatol Venereol 1998; 11Suppl. 2: S151Google Scholar
  37. 37.
    Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 1989; 32: 609–19PubMedCrossRefGoogle Scholar
  38. 38.
    Midgley G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol 1994; 31: S68–74PubMedCrossRefGoogle Scholar
  39. 39.
    A1-Sogair SM, Moawad MK, al-Humaiden YM. Fungal infection as a cause of skin disease in the eastern province of Saudi Arabia: prevailing fungi and pattern of infection. Mycoses 1991; 34: 333–7PubMedCrossRefGoogle Scholar
  40. 40.
    English MP, Atkinson R. Onychomycosis in elderly chiropody patients. Br J Dermatol 1974; 91: 67–72PubMedCrossRefGoogle Scholar
  41. 41.
    Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130Suppl. 43: 15PubMedCrossRefGoogle Scholar
  42. 42.
    Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996; 35: S2–5PubMedCrossRefGoogle Scholar
  43. 43.
    Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702–4PubMedCrossRefGoogle Scholar
  44. 44.
    Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Harris MI, Cowie CC, Stern MP, et al., editors. Diabetes in America. 2nd ed. NIH Publication No. 95-1468. Maryland: National Institutes of Health 1995: 409–28Google Scholar
  45. 45.
    Haria M, Bryson HM. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995; 49: 103–20PubMedCrossRefGoogle Scholar
  46. 46.
    Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycosis and dermatomycoses (an overview). Clin Exp Dermatol 1992; 17: 61–70PubMedCrossRefGoogle Scholar
  47. 47.
    Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4Suppl. 1: S23–30CrossRefGoogle Scholar
  48. 48.
    Polak AM. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol 1992; 17Suppl. 1: 8–12PubMedCrossRefGoogle Scholar
  49. 49.
    Roncari G, Ponelle Ch, Zumbrunnen R, et al. Percutaneous absorption of amorolfine following a single topical application of an amorolfine cream formulation. Clin Exp Dermatol 1992; 17: 33–6PubMedCrossRefGoogle Scholar
  50. 50.
    Abrams BB, Hänel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471–7PubMedCrossRefGoogle Scholar
  51. 51.
    Baran R, Viraben R, Bougaret S, et al. Effect of an 8% ciclopirox antifungal lacquer in onychomycosis: a multicenter, double-blind clinical trial versus systemic ketoconazole [abstract]. Second Congress of the European Academy of Dermatology and Venereology; 1991 Oct 9–13. Athens; 182Google Scholar
  52. 52.
    Ulbricht H, Wörz K. Therapy of onychomycosis due to moulds with ciclopirox nail lacquer. Mycoses 1994; 37: 97–100PubMedGoogle Scholar
  53. 53.
    Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution: an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111–5PubMedCrossRefGoogle Scholar
  54. 54.
    Hay RJ, Clayton YM, Moore MK. Acomparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175–7PubMedCrossRefGoogle Scholar
  55. 55.
    Rigopoulos D, Katsambas A, Antoniou C, et al. Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer. Acta Denn Venereol (Stockh) 1996; 76: 83–4Google Scholar
  56. 56.
    Gupta AK. The safety aspects of systemic and topical antifungal agents used in the management of onychomycosis. In: Kraemer K, Schuser S, editors. Hydroxy-pyridones as antifungal agents. Berlin: Springer-Verlag, 2000: 96–102Google Scholar
  57. 57.
    Gupta AK, Konnikov N, Lynde CW, et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. Eur J Dermatol 1999; 9: 633–8PubMedGoogle Scholar
  58. 58.
    Baran R. Amorolfine nail lacquer: a new transungual delivery system for nail mycoses. JAMA (South East Asia Suppl.) 1993; 9Suppl. 4: 5–6Google Scholar
  59. 59.
    Gupta AK, Daniel III CR. Factors that may affect the response of onychomycosis to oral antifungal therapy. Aust J Dermatol 1998; 39: 222–4CrossRefGoogle Scholar
  60. 60.
    Gupta AK, Daniel III CR. Onychomycosis: strategies to reduce failure, reinfection and relapse. Cutis 1998; 62: 189–91PubMedGoogle Scholar
  61. 61.
    Fräki J, Heikkila H, Kero M, et al. An open-label, non-comparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. Curr Ther Res 1997; 58: 481–91CrossRefGoogle Scholar
  62. 62.
    Haneke E, Delescluse J, Plinck EPB, et al. The use of itraconazole in onychomycosis. Eur J Dermatol 1996; 6: 7–10Google Scholar
  63. 63.
    Cohen PR, Scher RK. Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 1994; 31: S74–7PubMedCrossRefGoogle Scholar
  64. 64.
    Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. BMJ 1967; 3: 464–9PubMedCrossRefGoogle Scholar
  65. 65.
    Russell B, Frain-Bell W, Riddell RW, et al. Chronic ringworm infection of the skin and nails treated with griseofulvin. Lancet 1960; I: 1140–7Google Scholar
  66. 66.
    Villars W, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126: 61–9PubMedCrossRefGoogle Scholar
  67. 67.
    Knight TE, Shikuma CY, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991; 25: 398–400PubMedCrossRefGoogle Scholar
  68. 68.
    Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987; 294: 419–22CrossRefGoogle Scholar
  69. 69.
    Clissold SR Safety in clinical practice. In: Jones HE, editor. Ketoconazole today: a review of clinical experience. Manchester: Adis Press Ltd, 1987Google Scholar
  70. 70.
    Gupta AK, Sauder DN, Shear NH. Antifungals: an overview. Part I. J Am Acad Dermatol 1994; 30 (5 Pt 1): 677–700PubMedCrossRefGoogle Scholar
  71. 71.
    Gupta AK, Sauder DN, Shear NH. Antifungals: an overview. Part II. J Am Acad Dermatol 1994; 30(6): 911–33PubMedCrossRefGoogle Scholar
  72. 72.
    Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol 1995; 131: 937–42PubMedCrossRefGoogle Scholar
  73. 73.
    Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol 1997; 37: 979–88PubMedCrossRefGoogle Scholar
  74. 74.
    De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37: 969–74PubMedCrossRefGoogle Scholar
  75. 75.
    Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303–8PubMedCrossRefGoogle Scholar
  76. 76.
    Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis: an overview. Dermatol Clin 15; 1997: 121–35Google Scholar
  77. 77.
    Gupta AK, Lambert J. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Int J Dermatol 1999; 38: 53–64PubMedCrossRefGoogle Scholar
  78. 78.
    Evans EG, Sigurgeirsson B. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The L.I.O.N Study Group. BMJ 1999; 318: 1031–5PubMedCrossRefGoogle Scholar
  79. 79.
    Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Dermatol 1996; 34: 595–600CrossRefGoogle Scholar
  80. 80.
    Kejda J. Itraconazole pulse therapy vs terbinafine continuous dosing for toenail onychomycosis. Postgrad Med 1999; Spec No.: 12–5Google Scholar
  81. 81.
    Negroni R, Arechvala A, Bonvehi P. Treatment of onychomycosis due to mycelial fungi. Revista Argentina Micologia 1998; 21: 8–14Google Scholar
  82. 82.
    Havu V, Heikkila AH, Kuokkanen K, et al. A study to compare the efficacy of Lamisil® (terbinafine) and Diflucan® (fluconazole) in patients with onychomycosis [poster presentation 132]. J Eur Acad Dermatol Venereol 1996; 7Suppl. 2: S154Google Scholar
  83. 83.
    Tosti A, Piraccini DM, Vincenzi C, et al. Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. Pediatr Dermatol 1997; 14: 146–8PubMedCrossRefGoogle Scholar
  84. 84.
    Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359–66PubMedCrossRefGoogle Scholar
  85. 85.
    Kim J-A, Kyu-Joang A, Jong-Min K, et al. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995; 56: 1066–75CrossRefGoogle Scholar
  86. 86.
    Roberts DT, Richardson MD, Dwyer PK, et al. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 2Suppl. 1: 39–42CrossRefGoogle Scholar
  87. 87.
    Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 30Suppl. 43: 16–21CrossRefGoogle Scholar
  88. 88.
    Roberts DT. Terbinafine (Lamisil®) in the treatment of onychomycosis. J Dermatol Treat 1998; 9Suppl. 1: S3–8CrossRefGoogle Scholar
  89. 89.
    Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35: 958–61PubMedCrossRefGoogle Scholar
  90. 90.
    Hay RJ, Clayton YM. Fluconazole in the management of patients with chronic mucocutaneous candidiasis. Br J Dermatol 1988; 119: 683–4PubMedCrossRefGoogle Scholar
  91. 91.
    Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 2000; 22: 33–52PubMedCrossRefGoogle Scholar
  92. 92.
    Tosti A, Piraccini BM, Stinchi C, et al. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol 1996; 135: 799–802PubMedCrossRefGoogle Scholar
  93. 93.
    Scher RK, Barnett JM. Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole. J Am Acad Dermatol 1990; 23: 749–50PubMedCrossRefGoogle Scholar
  94. 94.
    De Doncker PRG, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173–7PubMedCrossRefGoogle Scholar
  95. 95.
    Smith SW, Sealy DP, Schneider E, et al. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 1995; 88: 1217–20PubMedCrossRefGoogle Scholar
  96. 96.
    Gupta AK, Horgan Bell C, Summerbell RC. Onychomycosis associated with Onychocola canadensis: 10 case reports and a review of the literature. J Am Acad Dermatol 1998; 39: 410–7PubMedCrossRefGoogle Scholar
  97. 97.
    Kawakami M, Suzuki K, Ishizuka T, et al. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther 1998; 36: 306–8PubMedGoogle Scholar
  98. 98.
    Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine, and their management. J Am Acad Dermatol 1999; 41: 237–49PubMedCrossRefGoogle Scholar
  99. 99.
    Gupta AK, Shear NH. A questionnaire study on the management of onychomycosis: a Canadian perspective. Int J Dermatol 1998; 37: 457–60PubMedCrossRefGoogle Scholar
  100. 100.
    De Doncker P, Meulemers L, Vertommen C, et al. Itraconazole safety summary. N133550. Beerse, Belgium: Janssen Research Foundation, 1998: (Data on file): 1–37Google Scholar
  101. 101.
    Pollack R, Billstein SA. Safety of oral terbinafine for toenail onychomycosis. J Am Podiatr Med Assoc 1997; 87: 565–70Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center (Sunnybrook site)University of TorontoTorontoCanada

Personalised recommendations